Acquisitions and Licensing Agreements - Additional Information (Details)
|
|
|
|
|
|
|
1 Months Ended |
3 Months Ended |
9 Months Ended |
12 Months Ended |
|
|
May 01, 2026
USD ($)
|
Sep. 04, 2025
USD ($)
shares
|
Feb. 24, 2025
USD ($)
Employees
|
Jun. 07, 2024
USD ($)
|
Jun. 06, 2024
USD ($)
|
Jun. 02, 2021
USD ($)
|
Aug. 31, 2026
USD ($)
|
Sep. 30, 2025
USD ($)
|
Nov. 30, 2024
USD ($)
$ / shares
shares
|
Sep. 30, 2026
USD ($)
shares
|
Sep. 30, 2025
USD ($)
|
Sep. 30, 2026
USD ($)
shares
|
Sep. 30, 2025
USD ($)
|
Dec. 31, 2024
USD ($)
|
Dec. 31, 2025
USD ($)
shares
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Acquisition related costs |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,000,000
|
|
| Compensation expense |
|
|
|
|
|
|
|
|
|
$ 16,978,000
|
$ 3,965,000
|
$ 34,031,000
|
$ 25,554,000
|
|
|
| Bargain purchase gain |
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
5,232,000
|
|
|
| Income tax benefit |
|
|
|
|
|
|
|
|
|
0
|
0
|
0
|
4,167,000
|
|
|
| Amortization expense related to finite-lived intangible assets |
|
|
|
|
|
|
|
|
|
1,100,000
|
1,000,000
|
3,400,000
|
2,300,000
|
|
|
| Contingent consideration milestone probability of achieving within 12 months |
|
|
|
|
|
|
|
|
|
$ 8,632,000
|
|
8,632,000
|
|
|
$ 2,500,000
|
| Bonus shares, cash remitted to satisfy related tax obligations |
|
|
|
|
|
|
|
|
|
|
|
$ 113,000
|
0
|
|
|
| Preferred stock, shares issued | shares |
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
0
|
| Research and development |
|
|
|
|
|
|
|
|
|
$ 64,359,000
|
49,139,000
|
$ 165,791,000
|
103,752,000
|
|
|
| Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Compensation expense |
|
|
|
|
|
|
|
|
|
10,336,000
|
2,082,000
|
21,623,000
|
17,830,000
|
|
|
| Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Compensation expense |
|
|
|
|
|
|
|
|
|
6,642,000
|
1,883,000
|
12,408,000
|
7,724,000
|
|
|
| Prolaio, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of outstanding shares acquired |
|
|
100.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
| Purchase consideration transferred |
|
|
$ 8,600,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Cash consideration |
|
|
4,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of contingent milestone |
$ 13,700,000
|
|
4,600,000
|
|
|
|
|
|
|
25,600,000
|
|
25,600,000
|
|
|
$ 3,800,000
|
| Acquisition related costs |
|
|
800,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Acquisition related costs incurred by company |
|
|
|
|
|
|
|
|
|
|
|
|
|
800,000
|
|
| Acquisition related costs incurred by acquiree |
|
|
|
|
|
|
|
|
|
|
|
|
|
200,000
|
|
| Net assets acquired |
|
|
13,812,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-lived intangibles |
|
|
25,400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Liabilities assumed |
|
|
13,823,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Deferred income tax liability |
|
|
4,512,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Assumed contingent consideration liability |
|
|
$ 3,300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Bargain purchase gain |
|
|
|
|
|
|
|
|
|
|
|
|
5,200,000
|
5,200,000
|
|
| Income tax benefit |
|
|
|
|
|
|
|
|
|
|
|
|
|
4,200,000
|
|
| Incremental stock-based compensation expense related to accelerated vesting of options upon acquisition |
|
|
|
|
|
|
|
|
|
|
|
|
14,400,000
|
1,600,000
|
|
| Amortization expense related to finite-lived intangible assets |
|
|
|
|
|
|
|
|
|
|
|
|
600,000
|
|
|
| Pro forma revenue |
|
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
| Estimated number of years to recreate technology |
|
|
3 years 8 months 12 days
|
|
|
|
|
|
|
|
|
|
|
|
|
| Estimated number of employees to recreate technology | Employees |
|
|
50
|
|
|
|
|
|
|
|
|
|
|
|
|
| Discounted rate of milestones required to be achieved |
|
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestones achieved |
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
|
| Change in fair value of contingent consideration liability |
|
|
|
|
|
|
|
|
|
(21,800,000)
|
0
|
21,700,000
|
0
|
|
|
| Milestone payments |
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
| Cash and cash equivalents |
|
|
$ 14,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Accounts payable |
|
|
2,710,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| PhysIQ, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of contingent milestone |
|
|
$ 3,300,000
|
|
|
|
|
|
|
4,000,000
|
|
4,000,000
|
|
|
3,900,000
|
| Business combination, contingent milestone payments |
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
|
| Acquisition related costs |
|
|
|
|
|
|
|
|
|
0
|
|
0.1
|
|
|
|
| Discounted rate of milestones required to be achieved |
|
|
10.00%
|
|
|
|
|
|
|
|
|
|
|
|
|
| Contingent consideration milestone probability of achieving within 12 months |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,500,000
|
| RSF |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Percentage of outstanding shares acquired |
|
|
|
|
100.00%
|
|
|
|
|
|
|
|
|
|
|
| Purchase consideration transferred |
|
|
|
|
$ 14,800,000
|
|
|
|
|
|
|
|
|
|
|
| Cash consideration |
|
|
|
|
3,500,000
|
|
|
|
|
|
|
|
|
|
|
| Business combination, contingent milestone payments |
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
|
| Milestones achieved |
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
|
| Cash and cash equivalents |
|
|
|
|
200,000
|
|
|
|
|
|
|
|
|
|
|
| Accounts payable |
|
|
|
|
1,300,000
|
|
|
|
|
|
|
|
|
|
|
| Milestone payment settled in cash |
|
|
|
|
|
|
|
$ 1,500,000
|
|
|
|
1,500,000
|
|
|
|
| In-process research and development asset |
|
|
|
|
15,900,000
|
|
|
|
|
|
|
|
|
|
|
| Payment of transaction costs |
|
|
|
|
700,000
|
|
|
|
|
|
|
|
|
|
|
| Settlement of outstanding indebtedness |
|
|
|
|
10,600,000
|
|
|
|
|
|
|
|
|
|
|
| RSF | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone payment obligation |
|
|
|
|
|
|
|
|
|
|
3,000,000
|
|
3,000,000
|
|
|
| Mr. Gianakakos | Prolaio, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Related party transaction, beneficial ownership percentage |
|
|
55.70%
|
|
|
|
|
|
|
|
|
|
|
|
|
| Repayment of promissory notes |
|
|
$ 4,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mr. Gianakakos | Milestone One | Prolaio, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone payments received |
12,900,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mr. Gianakakos | Milestone Two | Prolaio, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone payments received |
31,300,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Mr. Gianakakos | Milestone Three | Prolaio, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone payments received |
62,400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dr. Edelberg | Prolaio, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Related party transaction, beneficial ownership percentage |
|
|
17.10%
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dr. Edelberg | Milestone One | Prolaio, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone payments received |
3,600,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dr. Edelberg | Milestone Two | Prolaio, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone payments received |
9,800,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Dr. Edelberg | Milestone Three | Prolaio, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone payments received |
19,500,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Minimum | Prolaio, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Estimated average annual cost per employee to recreate technology |
|
|
$ 100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone payments |
5,000,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Minimum | Mr. Gianakakos | Prolaio, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone payments |
6,000,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Minimum | Dr. Edelberg | Prolaio, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone payments |
12,000,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maximum | Prolaio, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business combination, contingent milestone payments |
|
|
200,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Estimated average annual cost per employee to recreate technology |
|
|
$ 200,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of years milestones required to be achieved |
|
|
4 years
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone payments |
50,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maximum | PhysIQ, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business combination, contingent milestone payments |
|
|
$ 20,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Number of years milestones required to be achieved |
|
|
4 years
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maximum | RSF |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development and regulatory milestone payments |
|
|
|
|
26,500,000
|
|
|
|
|
|
|
|
|
|
|
| Sales milestones payments |
|
|
|
|
$ 249,500,000
|
|
|
|
|
|
|
|
|
|
|
| Maximum | Mr. Gianakakos | Prolaio, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone payments |
50,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone payments received |
106,600,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Maximum | Dr. Edelberg | Prolaio, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone payments |
100,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone payments received |
$ 32,900,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Developed Technology Rights [Member] | Prolaio, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-lived intangibles |
|
|
$ 25,400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| In Process Research and Development [Member] | Prolaio, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Finite-lived intangibles |
|
|
1,100,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Bonus Agreements [Member] | Prolaio, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Compensation expense |
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
|
| Bonus Agreements [Member] | Prolaio, Inc. | Location, Statement of Income, Balance [Axis]: us-gaap:GeneralAndAdministrativeExpense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Compensation expense |
|
|
|
|
|
|
|
|
|
|
0
|
|
11,700,000
|
|
|
| Bonus Agreements [Member] | Prolaio, Inc. | Location, Statement of Income, Balance [Axis]: us-gaap:ResearchAndDevelopmentExpense |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Compensation expense |
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
$ 2,600,000
|
|
|
| Bonus Agreements [Member] | Mr. Gianakakos | Prolaio, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business combination, contingent bonus amount |
|
|
9,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| Bonus Agreements [Member] | Dr. Edelberg | Prolaio, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business combination, contingent bonus amount |
|
|
$ 2,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
| License Agreement With Sanofi [Member] | RSF |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestones achieved |
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
|
| Milestone payments |
|
|
|
|
|
|
|
|
|
|
|
0
|
|
|
|
| Commercial milestone payments |
|
|
|
|
|
$ 14,800,000
|
|
|
|
|
|
|
|
|
|
| License Agreement With Mayo [Member] | RSF |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestones achieved |
|
|
|
|
|
|
|
|
|
0
|
|
0
|
|
|
|
| Milestone payments |
|
|
|
|
|
|
$ 100,000
|
|
|
|
|
0
|
|
|
|
| Development and regulatory milestone payments |
|
|
|
|
|
300,000
|
|
|
|
|
|
|
|
|
|
| Commercial milestone payments |
|
|
|
|
|
$ 1,300,000
|
|
|
|
|
|
|
|
|
|
| Ionis License Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone payments |
|
|
|
$ 375,000,000
|
|
|
|
|
|
|
|
|
|
|
|
| Upfront payment |
|
|
|
20,000,000
|
|
|
|
|
|
|
|
|
|
20,000,000
|
|
| Development and regulatory milestone payments |
|
|
|
35,000,000
|
|
|
|
|
|
|
|
|
|
|
|
| Sales milestones payments |
|
|
|
$ 340,000,000
|
|
|
|
|
|
|
|
|
|
|
|
| License Agreements with MyoKardia and BMS Co. [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestones achieved |
|
|
|
|
|
|
|
|
|
$ 0
|
|
0
|
|
|
|
| Milestone payments |
|
|
|
|
|
|
|
|
|
|
|
$ 0
|
|
|
|
| Fair value of shares per share | $ / shares |
|
|
|
|
|
|
|
|
$ 19.1
|
|
|
|
|
|
|
| Fair value of shares |
|
|
|
|
|
|
|
|
$ 29,500,000
|
|
|
|
|
|
|
| Research and development |
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 29,500,000
|
|
| License Agreements with MyoKardia and BMS Co. Related to Dani Agreement [Member] | Maximum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development and regulatory milestone payments |
|
|
|
|
|
|
|
|
42,500,000
|
|
|
|
|
|
|
| Sales milestones payments |
|
|
|
|
|
|
|
|
265,000,000
|
|
|
|
|
|
|
| License Agreements with MyoKardia and BMS Co. Related to Par4 Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development and regulatory milestone payments, tranche one |
|
|
|
|
|
|
|
|
12,500,000
|
|
|
|
|
|
|
| Development and regulatory milestone payments, tranche two |
|
|
|
|
|
|
|
|
13,625,000
|
|
|
|
|
|
|
| Sales milestones payments |
|
|
|
|
|
|
|
|
265,000,000
|
|
|
|
|
|
|
| License Agreements with MyoKardia and BMS Co. Related to Par4 Agreement [Member] | Maximum |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Development and regulatory milestone payments |
|
|
|
|
|
|
|
|
$ 10,000,000
|
|
|
|
|
|
|
| Series B Preferred Stock | Bonus Agreements [Member] | Prolaio, Inc. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business combination, consideration transferred, equity interest, number of shares issued | shares |
|
374,360
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business combination, consideration transferred, equity interest, value of shares issued |
|
$ 8,000,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Bonus shares, cash remitted to satisfy related tax obligations |
|
$ 6,400,000
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Series A Preferred Stock |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Fair value of shares per share | $ / shares |
|
|
|
|
|
|
|
|
$ 19.1
|
|
|
|
|
|
|
| Fair value of shares |
|
|
|
|
|
|
|
|
$ 29,500,000
|
|
|
|
|
|
|
| Series A Preferred Stock | License Agreements with MyoKardia and BMS Co. [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred stock, shares issued | shares |
|
|
|
|
|
|
|
|
1,544,576
|
|
|
|
|
|
|
| Series A Preferred Stock | License Agreements with MyoKardia and BMS Co. Related to Dani Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred stock, shares issued | shares |
|
|
|
|
|
|
|
|
1,251,107
|
|
|
|
|
|
|
| Series A Preferred Stock | License Agreements with MyoKardia and BMS Co. Related to Par4 Agreement [Member] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Preferred stock, shares issued | shares |
|
|
|
|
|
|
|
|
293,469
|
|
|
|
|
|
|
| Accrued and Other Current Liabilities [Member] | RSF |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Business Combination [Line Items] |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| Milestone payment accrued |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$ 1,500,000
|